Difference and clinical significance of serum GP73 between alcoholic liver disease and non-alcohol fatty liver disease
Lists
Only you see this
Abstract
Objective The present study was designed to evaluate the clinical significance of serum GP73 in patients with alcohol liver disease. Methods Thirty-two patients with alcoholic liver disease (ALD), 40 patients with non-alcohol fatty liver disease(NFLAD), and 40 apparently healthy individuals were included in this study. Results Compared with Those of healthy control population(43.91±19.02 ng/ml), the serum GP73 levels in ALD patients(93.39±66.91 ng/ml) were significantly increased, and also markedly higher than those of NFLAD patients (55.38±21.00 ng/ml). Taken the NFALD ashealthy controls population, and ALD population aspatients , the GP73 may be used to differentiate the ALD from NFLAD. The area of ROC analysis was 0.66(95%CI: 0.52~0.80, P=0.02). We set 75.65 ng/ml as the cut-off value for ALD diagnosis, the sensitivity and specificity were 50.0% and 85.0% respectively. Conclusion Serum GP73 levels in ALD patients were significantly higher than those of NFALD patients. GP73 may be a new marker for differentiating ALD from NFALD. Key words: Alcoholic liver disease; Non-alcohol fatty liver disease; Golgi protein 73; Differentiating diagnosis
BibTeX
@inproceedings{zhou2017difference,
author = {Aiguo Zhou and Jun Hou and Xin Feng and Yubo Huang and Boan Li},
title = {{Difference and clinical significance of serum GP73 between alcoholic liver disease and non-alcohol fatty liver disease}},
booktitle = {Chinese},
year = {2017},
doi = {10.3760/cma.j.issn.1003-9279.2017.02.017},
}Loading related content...